drugset / Trial / NCT02226978

Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers

NCT02226978

Phase 1 Completed 29 enrolled Boehringer Ingelheim
CrossoverOpen-labelTreatment

Summary

Assessment of the interaction of tipranavir/ritonavir (TPV/RTV) and valaciclovir (VAL), a prodrug of aciclovir (ACV)

Timeline

Start
2007-02
Primary completion
2007-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ritonavir Other / unclassified 200 mg
Subject Tipranavir Small molecule 500 mg
Subject Valaciclovir Unknown 500 mg

Indications

No indication recorded.